Newspaper Publication for Unaudited Standalone Financial Results for the third quarter & nine months ended on 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has notified the stock exchanges that it published the extract of its unaudited standalone financial results for the third quarter and nine months ended December 31, 2025 in Business Standard (English) and Dainik Nalanda Express (Marathi) on February 12, 2026. The results were approved by the Board on February 10, 2026. Standalone revenue from operations for Q3 FY26 stood at Rs 511.88 lakhs, down from Rs 809.28 lakhs in the previous quarter and Rs 540.74 lakhs in Q3 FY25. The company slipped into a standalone net loss of Rs 156.12 lakhs in Q3 FY26 against a profit of Rs 183.54 lakhs in Q2 FY26 and Rs 37.66 lakhs in Q3 FY25. For the nine months, revenue grew to Rs 1,845.96 lakhs from Rs 1,622.23 lakhs last year, but net profit fell to Rs 74.03 lakhs from Rs 135.02 lakhs, with Q3 standalone EPS at Rs (1.52).
This is a routine SEBI compliance filing (newspaper publication) of already-disclosed results, with no fresh business trigger. However, the underlying Q3 standalone numbers are weak — a sharp sequential revenue decline and a swing to loss may weigh on short-term investor sentiment even though nine-month revenue shows year-on-year growth.